Paul A. Laviolette - 11 May 2026 Form 4/A - Amendment Insider Report for PULSE BIOSCIENCES, INC. (PLSE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: PLSE
Reported as of: 11 May 2026
Net transaction value: +$295,350
SEC form: 4/A - Amendment
Accepted by SEC: 11 May 2026, 20:52:41 UTC
Original report date: 11 May 2026
Prior SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact

Key filing fact

Paul A. Laviolette filed Form 4/A - Amendment for PULSE BIOSCIENCES, INC. (PLSE) on 11 May 2026.

Key facts

This page summarizes Paul A. Laviolette's Form 4/A - Amendment filing for PULSE BIOSCIENCES, INC. (PLSE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 May 2026, 20:52.

Change

Previous filing in this sequence was filed on 08 May 2026.
Current net transaction value: +$295,350.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001191249 Primary reporting owner

LAVIOLETTE PAUL A

Relationship: Chief Executive Officer, Director
Address: C/O PULSE BIOSCIENCES, INC., 601 BRICKELL KEY DRIVE, SUITE 1080, MIAMI
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Signature date: 11 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLSE transaction

Common Stock

Purchase

Transaction value: $295,350
Shares: +15,000
Change %: +1773%
Price: $19.69
Shares after: 15,846
Date: 11 May 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.

Footnote F2

The shares reported herein were acquired in a negotiated through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.

Footnote F3

Includes shares purchased through the Company's Employee Stock Purchase Plan in March 2026.